Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX) announced inducement equity grants made January 30, 2025 to seven new non‑executive employees totaling 198,250 stock options under its 2024 Inducement Equity Incentive Plan.

Options have an exercise price of $28.15 (equal to the closing price on the grant date) and vest 25% after one year then 1/48th monthly thereafter, subject to continued service, granted pursuant to Nasdaq Listing Rule 5635(c)(4).

Key Figures

Current price: $28.15 Inducement option shares: 198,250 shares Number of employees: 7 employees +3 more

6 metrics

Current price $28.15 Pre-news close from market context

Inducement option shares 198,250 shares Total options granted to 7 new non-executive employees

Number of employees 7 employees Recipients of inducement stock options

Option exercise price $28.15 per share Equal to EWTX closing price on January 30, 2025 grant date

Initial vesting cliff 25% Vests on one-year employment anniversary for each employee

Ongoing vesting rate 1/48th monthly Remaining options vest monthly after first anniversary, service-based

Market Reality Check

Price: $28.89 Vol: Volume 836,002 vs 20-day ...

normal vol

$28.89 Last Close

Volume Volume 836,002 vs 20-day average 1,159,488 (relative volume 0.72) indicates quieter trading ahead of this update. normal

Technical Price $28.15 is trading above the $17.45 200-day MA, and about 7.64% below the $30.48 52-week high.

Peers on Argus

EWTX showed a pre-news move of -2.19%. Several biotech peers (VERA, VRDN, ARDX, ...

EWTX showed a pre-news move of -2.19%. Several biotech peers (VERA, VRDN, ARDX, AUPH, PHVS) also traded lower on the day, with moves from about -0.41% to -2.41%, but the momentum scanner did not flag a coordinated sector move.

Historical Context

5 past events · Latest: Jan 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 13	Corporate update	Positive	+3.4%	Outlined 2026 priorities, pivotal data timing, and NDA submission plans.
Jan 06	Conference presentation	Neutral	-2.7%	Announced J.P. Morgan conference presentation and webcast logistics.
Jan 05	Inducement grants	Neutral	-0.8%	Inducement stock options for new hires under 2024 Inducement Plan.
Dec 24	Clinical trial data	Positive	+25.5%	Completed CIRRUS-HCM Parts B/C with favorable safety and biomarker data.
Dec 02	Inducement grants	Neutral	-9.1%	Single-hire inducement option grant with standard vesting terms.

Pattern Detected

Clinical data and major pipeline updates drew the strongest positive reactions, while routine items like conference notices and inducement grants saw mixed to negative moves.

Recent Company History

Over the past few months, Edgewise cycled through routine corporate items and key pipeline milestones. A Dec 24, 2025 CIRRUS‑HCM update with favorable safety and efficacy signals drove a strong 25.5% gain, while a Jan 13, 2026 corporate update outlining 2026 priorities and an expected NDA in H1 2027 produced a modest 3.4% rise. By contrast, earlier inducement grant announcements and a conference presentation notice were associated with small to moderate declines, framing today’s inducement awards as another routine compensation event.

Market Pulse Summary

This announcement documents standard inducement stock option grants for seven new employees under th...

Analysis

This announcement documents standard inducement stock option grants for seven new employees under the 2024 Inducement Equity Incentive Plan, at an exercise price of $28.15 and with time‑based vesting. Historically, similar Edgewise updates have had limited lasting impact compared with major clinical and pipeline milestones, such as the positive CIRRUS‑HCM data on Dec 24, 2025. Investors tracking the name often focus more on pivotal readouts and regulatory timelines than on routine compensation grants.

Key Terms

inducement stock options, exercise price, equity incentive plan, nasdaq listing rule 5635(c)(4)

4 terms

inducement stock options financial

"Edgewise granted inducement stock options to purchase a total of 198,250 shares"

Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.

exercise price financial

"Each inducement stock option has an exercise price of $28.15 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

equity incentive plan financial

"pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan")"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

nasdaq listing rule 5635(c)(4) regulatory

"granted as inducements ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

BOULDER, Colo., Feb. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on January 30, 2025, Edgewise granted inducement stock options to purchase a total of 198,250 shares of Edgewise's common stock to 7 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").    

Each inducement stock option has an exercise price of $28.15 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.

Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4). 

About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn and X.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302675780.html

SOURCE Edgewise Therapeutics

FAQ

What did Edgewise (EWTX) announce on February 2, 2026 about inducement grants?

Edgewise announced inducement stock options totaling 198,250 shares granted January 30, 2025 to seven new non‑executive employees. According to the company, grants were made under its 2024 Inducement Equity Incentive Plan as permitted by Nasdaq Listing Rule 5635(c)(4).

How many employees received options and what was the total grant size for EWTX?

Seven new non‑executive employees received inducement awards totaling 198,250 stock options. According to the company, the grants were issued in connection with the commencement of their employment on January 30, 2025.

What are the vesting terms for the Edgewise (EWTX) inducement stock options?

Each option vests 25% on the one‑year anniversary of the employee start date, then vests an additional 1/48th monthly thereafter. According to the company, vesting is subject to the employee's continued service and plan terms.

What exercise price was set for the EWTX inducement options and how was it determined?

The exercise price for each inducement option is $28.15 per share, equal to the closing price of Edgewise common stock on the grant date. According to the company, that price reflects the market close on January 30, 2025.

Why were the inducement awards granted under Nasdaq Listing Rule 5635(c)(4) for EWTX?

The awards were granted as inducements to enter employment and were made in accordance with Nasdaq Listing Rule 5635(c)(4). According to the company, the grants were material to recruit the seven new non‑executive hires and followed the Inducement Plan.